MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/txd.0000000000001851

Медицинская библиотека · Transplantation direct · 2025

Immune Checkpoint Inhibitors in Kidney Transplant Recipients: A French Multicenter Retrospective Cohort Study.

Legris Tristan, Sallée Marion, Charmetant Xavier, Thaunat Olivier, Matignon Marie, Joher Nizar, Pernin Vincent, Sicard Antoine, Kaminski Hannah, Couzi Lionel, Moal Valérie

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Kidney transplant recipients (KTRs) are at elevated risk of malignancy. Data on the safety and efficacy of immune checkpoint inhibitors (ICIs) in this population remain limited. We aimed to reassess the benefit-risk profile of ICI therapy in KTRs using a multicenter cohort, in the recent era.

METHODS

We conducted a retrospective cohort study of all KTRs treated with ICIs for advanced or metastatic cancer, across 6 transplant centers. We evaluated cancer response, acute rejection (AR) incidence, graft survival, and patient survival.

RESULTS

From 2015 to 2024, 34 KTRs were analyzed. The most common cancers were cutaneous (56%) and non-small cell lung cancer (32%). Pembrolizumab was the most used ICI (53%). The objective response rate was 38%, with a median progression-free survival of 5.5 mo and an overall survival of 10.7 mo. Biopsy-proven AR occurred in 26.5% of patients, at a median time of 52 d after ICI start. All rejection episodes involved T cells, and one-third showed additional humoral features. No clinical predictors of AR were identified. Among all patients, 29% had a favorable outcome (tumor response without ICI-induced graft loss), 12% experienced a tumor response with graft loss, 59% had progression disease without graft loss, and 3% experienced the worst outcome (progression disease with graft loss).

CONCLUSIONS

Our study suggests that ICI therapy is a viable option for KTRs with poor-prognosis cancers, demonstrating a 38% tumor response rate and a lower incidence of graft loss (15%) compared with previously reported rates. Prospective studies are needed to optimize the use of ICI in KTRs.

Для цитирования: Legris Tristan, Sallée Marion, Charmetant Xavier, Thaunat Olivier, Matignon Marie, Joher Nizar, Pernin Vincent, Sicard Antoine, Kaminski Hannah, Couzi Lionel, Moal Valérie. Immune Checkpoint Inhibitors in Kidney Transplant Recipients: A French Multicenter Retrospective Cohort Study.. Transplantation direct. 2025. DOI: 10.1097/txd.0000000000001851.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.